MYL - Mylan N.V.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
+0.12 (+0.45%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close26.73
Bid26.86 x 800
Ask27.00 x 3000
Day's Range26.57 - 27.16
52 Week Range26.00 - 42.50
Avg. Volume5,490,509
Market Cap13.853B
Beta (3Y Monthly)1.66
PE Ratio (TTM)39.49
EPS (TTM)0.68
Earnings DateMay 7, 2019 - May 13, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2007-06-27
1y Target Est36.31
Trade prices are not sourced from all markets
  • PR Newswire3 days ago

    TB Alliance and Mylan Announce Global Collaboration to Commercialize Investigational Drug Pretomanid as Part of Two Regimens to Treat Tuberculosis (TB)

    NEW YORK and HERTFORDSHIRE, England and PITTSBURGH, April 18, 2019 /PRNewswire/ -- Non-profit drug developer, TB Alliance, and pharmaceutical company, Mylan N.V. (MYL), today announced a global collaboration to make the experimental drug pretomanid accessible for use in two investigational drug regimens for pulmonary tuberculosis (TB). It also is the leading cause of death among people with HIV/AIDS2 and accounts for more than 1 in 4 fatalities from antimicrobial resistance annually.3 TB occurs in every part of the world.

  • Reuters5 days ago

    Recordati to seek Canadian approval for kidney disease drug

    Italy's Recordati said on Tuesday it plans to seek Canadian approval for its drug Cystagon, which treats a rare kidney disease, in a potential blow to Horizon Pharma,, which makes the only drug approved for treatment in Canada. Cystagon and Horizon's drug Procysbi use the same active ingredient to treat nephropathic cystinosis, a genetic disorder that can cause fatal kidney damage. Only about 100 people in Canada have the disease, but at list prices Procysbi costs C$325,000 ($243,336.33) per year, according to Canadian regulators.

  • Allergan Falls as Supreme Court Dismisses Restasis Litigation
    Zacks5 days ago

    Allergan Falls as Supreme Court Dismisses Restasis Litigation

    Allergan's (AGN) key drug, Restasis' prospects hurt as the U.S. Supreme Court upholds the ruling of a lower court, which invalidated certain patents protecting the drug.

  • Reuters6 days ago

    U.S. Supreme Court rejects Allergan bid to use tribe to shield drug patents

    The U.S. Supreme Court on Monday cast aside pharmaceutical company Allergan Plc's unorthodox bid to shield patents from a federal administrative court's review by transferring them to a Native American tribe. The justices left in place a lower court ruling upholding the authority of a U.S. Patent and Trademark Office tribunal to decide the validity of patents covering Allergan's dry eye drug Restasis, refusing to hear the company's appeal.

  • GuruFocus.com7 days ago

    Stocks That Fell to 3-Year Lows in the Week of April 12

    Bristol-Myers Squibb Company (BMY), Annaly Capital Management Inc. (NLY), Newell Brands Inc. (NWL) and Mylan NV (MYL) have declined to their three-year lows. Bristol-Myers Squibb Company is an American international pharmaceutical company that manufactures prescription pharmaceuticals in various therapeutic areas including cancer, cardiovascular diseases, diabetes, hepatitis, and HIV. The trailing 12-month dividend yield of Bristol-Myers Squibb Company stocks is 3.53%.

  • Acorda to Gain From Inbrija Sales and Neurological Pipeline
    Zacks10 days ago

    Acorda to Gain From Inbrija Sales and Neurological Pipeline

    Acorda (ACOR) aims to boost sales with the launch of its newly FDA-approved Parkinson's disease drug, Inbrija. The company's pipeline looks promising as well.

  • Markit12 days ago

    See what the IHS Markit Score report has to say about Mylan NV.

    Mylan NV NASDAQ/NGS:MYLView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low * Economic output in this company's sector is expanding Bearish sentimentShort interest | PositiveShort interest is extremely low for MYL with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting MYL. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, growth of ETFs holding MYL is favorable, with net inflows of $27.63 billion. This is among the highest net inflows seen over the last one-year and the rate of additional inflows appears to be increasing. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Striving to Create Better Health for a Better World: Mylan's Global Social Responsibility 2018 Progress Report Now Available
    PR Newswire18 days ago

    Striving to Create Better Health for a Better World: Mylan's Global Social Responsibility 2018 Progress Report Now Available

    HERTFORDSHIRE, England and PITTSBURGH, April 3, 2019 /PRNewswire/ -- Global pharmaceutical company Mylan N.V. (MYL) is committed to doing its part to achieve a positive, sustained impact on the world around us, from ensuring responsible operations that provide high quality medicine in more than 165 countries across developed and developing markets to continuing to advocate for the 7 billion patients the company seeks to serve. As part of that commitment, Mylan today released its Global Social Responsibility 2018 Progress Report, which provides an enterprise-wide overview of Mylan's operations as they relate to various environmental, social and governance (ESG) matters.

  • Here’s What Hedge Funds Think About Mylan N.V. (MYL)
    Insider Monkey20 days ago

    Here’s What Hedge Funds Think About Mylan N.V. (MYL)

    Investing in small cap stocks has historically been a way to outperform the market, as small cap companies typically grow faster on average than the blue chips. That outperformance comes with a price, however, as there are occasional periods of higher volatility. The fourth quarter of 2018 is one of those periods, as the Russell […]

  • BMO’s Got A Point About Teva Stock, But Are Investors Willing To Listen?
    InvestorPlace20 days ago

    BMO’s Got A Point About Teva Stock, But Are Investors Willing To Listen?

    The past three years have been tough for investors in Teva Pharmaceutical Industries (NYSE:TEVA). The share have gone from their 2015 peak near $72 to a current price below $16, slipping out of a rebound effort that took shape in 2018. TEVA stock has peeled back from last year's high near $26, after bottoming near $11 in late-2017.Nothing seems to excite investors for very long.Analysts -- some analysts anyway -- are starting to take notice of subtle changes, putting several upgrades in place during the first quarter of this year.InvestorPlace - Stock Market News, Stock Advice & Trading TipsMost of those calls are still cautious ones, with the most recent one from BMO Capital Markets being no exception to that norm. The analysts at Bank of Montreal (NYSE:BMO) see evidence of a turnaround taking shape, but remain concerned that Teva's generics business and pipeline aren't quite as robust as the firm would like.In taking a closer look at the analyst community's changing consensus, though, it's possible these professionals are quietly pointing toward more potential than most investors currently see in Teva stock. Disguised BullishnessBMO analyst Gary Nachman doesn't believe recent launches of Huntington's disease treatment Austedo and migraine treatment Ajovy will "be enough to put the overall company on a solid growth trajectory," adding concern about the limited "visibility on the generic pipeline, where we believe TEVA is behind its peers." * 7 Reasons to Buy Housing Stocks in 2019 Still, there's enough potential in Teva Pharmaceuticals stock for BMO to initiate coverage on it, rating it a Market Perform … a call that leaves the door wide open to updated ratings in either direction.Nachman had a valid point, too, about the company's generics pipeline. From what can be gleaned about it, it's not necessarily scintillating.That's not exactly news though, to investors or to the company, or to other analysts for that matter. That's been a lingering problem at Teva to most professional and amateur observers.It may also be the groundwork for upgrades driven by the very pipeline BMO is concerned about.Even if unintentionally, most other analysts are doing the same. As of the latest look, the pros collectively rate TEVA stock at only a little better than a "Hold" but simultaneously sport a consensus price target of $20.50. That's 30% better than the stock's current price. Click to EnlargeThe superficial mismatch isn't stunningly unusual; most stocks are priced below their consensus targets regardless of the collective buy/sell opinion on those names.This particular disparity, however, is also mismatched with the "read between the lines" rhetoric. Teva stock has been upgraded three times so far this year, with two new-coverage initiations at Hold that may be precursors to expected upgrades.If those upgrades are going to materialize, though, they're going to do so thanks to only a handful of names in the company's drug portfolio and pipeline. Identifying Growth DriversWhile its bench of drugs is deep, Teva's flagship product is multiple sclerosis drug Copaxone.In its prime, Copaxone had no peers. It's past its prime though, largely thanks to generic alternatives that have hit the market just in the past couple of years. Mylan (NASDAQ:MYL) got the nod from the FDA in late 2017; Novartis (NYSE:NVS) is in the MS treatment race with its own version of Copaxone as well.Those rival drugs have taken a measurable toll. In 2016, Teva sold $4.2 billion worth of Copaxone, but that volume was almost halved to a little less than $2.4 billion last year.The bulk of the adverse impact of the generic multiple sclerosis treatment, however, is likely in the rearview mirror. Going forward, Teva shouldn't be fighting as much of a headwind on at least that one front.In the meantime, Ajovy and Austedo may be bigger growth drivers than BMO's Nachman is currently be letting on.Migraine drug Ajovy taps into a relatively underserved market. While Eli Lilly (NYSE:LLY) and Amgen (NASDAQ:AMGN)/Novartis are also in the same market with Emgality and Aimovig, respectively, analysts at Israel's IBI anticipates peak sales of between $1.6 billion and $2.4 billion for Teva's Ajovy. Meanwhile, RBC Capital Markets analyst Randall Stanicky forecasts peak sales of $1.3 billion for Austedo. * 10 Tech Stocks That Transformed Their Business That level of success, along with the rest of the company's portfolio and pipeline, should restore solid growth even as the benefit of Copaxone shrinks.Also keep an eye on subsidiary Anda, which saw sales growth of 26% last quarter, reaching $363 million.The upshot for owners of Teva stock is that it's crystal clear where growth needs to come from. It won't be difficult to see what's working, and what's not, given the relatively small portfolio and pipeline. Bottom Line on Teva StockAgain, without saying as much, most Teva stock analysts may be quietly expecting a respectable turnaround, but are thus far unwilling to say as much without more tangible proof it's taking shape.Analysts' careers don't just depend on quality analysis, but on being 'right' even if that standard is unspoken. These professionals may be cautiously leading investors to a marketwide conclusion that the forward-looking P/E of 6.0 for Teva stock is simply too cheap to pass up, given the potential -- even if not the assured promise -- of a turnaround.Undoubtedly though, the rhetoric about slowing Copaxone's deterioration and the growth of Austedo and Ajovy will help shape investors' and analysts' opinion. Investors would be wise to focus on those three drugs as a barometer of how the market feels about Teva stock.As of this writing, James Brumley did not hold a position in any of the aforementioned securities. You can learn more about James at his site,, or follow him on Twitter, at @jbrumley. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 8 Genomic Testing Stocks That Can Ease the Sting of Theranos * 4 Pot Stocks That Could Be Fizzling Out * 7 Mid-Cap Growth Stocks That Could Be the Next Amazon or Netflix Compare Brokers The post BMO's Got A Point About Teva Stock, But Are Investors Willing To Listen? appeared first on InvestorPlace.

  • Mylan (MYL) Up 8.6% Since Last Earnings Report: Can It Continue?
    Zacks24 days ago

    Mylan (MYL) Up 8.6% Since Last Earnings Report: Can It Continue?

    Mylan (MYL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Falling Earnings Estimates Signal Weakness Ahead for Mylan (MYL)
    Zacks24 days ago

    Falling Earnings Estimates Signal Weakness Ahead for Mylan (MYL)

    Mylan (MYL) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.

  • Analysts Have Reduced Target Prices for Mylan in March
    Market Realist27 days ago

    Analysts Have Reduced Target Prices for Mylan in March

    How Generic Pharmaceutical Stocks Are Positioned this Month(Continued from Prior Part)Analysts’ recommendations and target prices Wall Street analysts expect an upside potential of 26.56% for Mylan (MYL), based on the company’s closing price on

  • MarketWatchlast month

    Biogen stock downgraded to neutral from buy at UBS

    Analysts at UBS on Friday downgraded shares of Biogen Inc. to neutral from buy, while cutting their price target on the stock to $242 from $395. "The failure of aducanumab leaves Biogen with a lack of visibility around a path back to top-line growth, and increasingly present threats to the base-business that investors had been willing to look past given the promise of Alzheimer's," analysts led by Carter Gould wrote. He cited competition to spinal muscular atrophy drug Spinraza from Roche Holding's ridiplam and threats to a 2028 patent on the company's multiple sclerosis drug Tecfidera, which is under review by trademark officials after competitor Mylan N.V. filed a patent challenge in July. Biogen's stock, which fell 1.5% in premarket trade Friday, plunged 29% on Thursday after the company announced it would be discontinuing Phase 3 trials for aducanumab, its much-hyped Alzheimer's drug. Shares of the drugmaker have fallen 25% in the year to date, while the S&P 500 has gained 13.9%.

  • Glaxo Presents Encouraging Data on Endometrial Cancer Drug
    Zackslast month

    Glaxo Presents Encouraging Data on Endometrial Cancer Drug

    Glaxo (GSK) presents encouraging data from phase I/II study on endometrial cancer drug, dostarlimab.

  • MarketWatchlast month

    Mylan voluntarily recalls two lots of its levoleucovorin injection

    Mylan N.V. said on Monday that it is voluntarily recalling two lots of its levoleucovorin injection due to the discovery of foreign particulates in the drug. Levoleucovorin is used to reduce harmful effects of methotrexate, a medication used to treat patients with osteosarcoma. It is also used in combination chemotherapy with 5-fluorouracil to treat patients with advanced metastatic colorectal cancer. Mylan said it discovered the presence of copper salts in the levoleucovorin during 12-month stability testing. Such particulates can lead to severe health complications like vasculitis, allergic reactions and pulmonary embolism. The drug maker has not received any reports of adverse events related to the recall and said it notified its distributors and customers by letter. Shares of Mylan have fallen 2.2% in the year to date, while the S&P 500 has gained 11.1%.

  • Mylan Institutional LLC Initiates Voluntary Nationwide Recall of Levoleucovorin Injection Due to the Presence of Particulate Matter
    PR Newswirelast month

    Mylan Institutional LLC Initiates Voluntary Nationwide Recall of Levoleucovorin Injection Due to the Presence of Particulate Matter

    ROCKFORD, Ill., March 18, 2019 /PRNewswire/ -- Mylan Institutional LLC is conducting a voluntary nationwide recall of two lots (see table below) of Levoleucovorin Injection, 250 mg/25 mL tothe consumer/user level. The lots were manufactured by Alidac Pharmaceuticals Limited and distributed by Mylan Institutional LLC. The Levoleucovorin Injection is being recalled due to the presence of particulate matter identified as copper salts. The particulate matter was discovered during 12-month stability testing. Administration of a sterile injectable that has foreign particulates has the potential of severe health consequences.

  • GlobeNewswirelast month

    Mapi Pharma Receives Government of Israel Funding for the Establishment of a Finished Dosage Form Facility for the Manufacturing of GA Depot Pharmaceuticals

    Mapi Pharma Ltd., a fully integrated, clinical, late stage biopharmaceutical company, announced today that it has received complementary funding from the Israeli Ministry of the Economy to build a new sterile production plant for GA Depot injectable products. The approved financing plan is for a pioneering production plant for the manufacturing of a slow release formulation of Glatiramer Acetate (GA) (Copaxone®) for treating multiple sclerosis.

  • 5 Undervalued Stocks to Invest In
    InvestorPlacelast month

    5 Undervalued Stocks to Invest In

    [Editor's note: This story was previously published in February 2019. It has since been updated and republished.]Overall, the stock market has made a huge improvement at the start of 2019 from where it ended in 2018; it has been a complete turnaround from last year's drop, when stocks entered bear-market territory.But even though many stocks have completely erased all of their losses and made it back into the green, not all stocks have done so well. What this means is that while there are still plenty of duds out there, there are also a few undervalued stocks to buy; it has just become a little trickier to find them amid all the flashy comeback stories.InvestorPlace - Stock Market News, Stock Advice & Trading TipsTo find the best stocks to invest in now,disciplined investors might start with their own watch list, which should contain "wish list" stocks that are usually too expensive or have been put there to be on the backburner for later. Among such stocks, companies that got left out of the rally are the most compelling. Even better, the best undervalued stocks to invest in are those that dropped by double-digit percentages during the current rally.Why is that?Markets that are pricing in the negative news typically lower the risk for investors. Such companies may work to resolve the business problem at hand, which improves its prospects and leads to a higher share price in the long run. As long as the bad news reported is a temporary setback and the business model is not broken, the risks behind buying a stock on a dip are lower. * 7 Winning High-Yield Dividend Stocks With Payouts Over 5% With all of that in mind, here are five undervalued stocks to invest in that aren't as scary as they seem. Sony (SNE)Investors expected more from Sony's (NYSE:SNE) earnings report when the company posted results on Feb. 1. Revenue of 2.4 trillion yen in the third-quarter missed estimates for 2.67 trillion yen.Adding salt to the wound, many SNE investors are fretting over Sony's weaker sales outlook, with smartphone and camera sales lagging. On the flipside, the PlayStation 4 business still could rebound. Even though the console cycle is many years old, customers will continue to buy new game titles. And in the smartphone space, a refresh in the second half of this year may give customers a reason to buy a new Sony device again.Sony is clearly not a broken company, so the stock's drop from $50 on Feb. 1 to $46 appears overdone. Trading less than 10% above its 52-week low and about 25% below its 52-week high, Sony stock clearly deserves its spot among the best undervalued stocks to consider now. Celestica (CLS)Celestica (NYSE:CLS) reported fourth-quarter revenue of $1.73 billion, up 10% from last year. Net earnings rose $46.5 million to $60.1 million, bringing in earnings of 44 cents a share. However, investors were unimpressed with the weak sequential revenue in its Communications, ATS and CCS segments, which were either flat or down. Still, revenue from all segments grew in the double digits from last year.Celestica ended the year with $422 million in cash and cash equivalents. Net cash fell $335 million for the year. And the balance sheet is not as strong as it could be, with non-IFRS debt leverage at 2.6X.The company supplies equipment in ATS -- aerospace and defense, industrial, smart energy, health tech and capital equipment. Its enterprise unit consists of servers and storage. Why then, should investors believe the company will offset the weakness it faces in the eroding semiconductor market?Celestica is cutting costs in operations to align the business with the lower revenue. It will continue to build its capital equipment business. Management believes the fundamentals in this space will only improve in the long run. As next-generation adoption in display continues, its OLED business, for example, will add to its bottom line.Celestica stock is an undervalued play worth considering. Allergan (AGN)Generic drug supplier Allergan (NYSE:AGN) fell over 10% in late January and early February for two reasons. First, its fourth-quarter earnings report did not please investors. Operating income sank 11.8% year-over-year, and revenue fell 5.8% YoY to $4.08 billion.On Feb. 1, the Food and Drug Administration approved Evolus' (NASDAQ:EOLS) Jeuveau. This product competes directly with Allergan's Botox. Pricing could come in at 20% below that of Botox, putting pressure on Allergan's bottom line.Be warned: it's likely that AGN stock will continue to sell off as investors price in the worst case scenario for Botox. Even though management already expects some pricing erosion, it is confident that the sales volume will taper off slowly. But this is good news for investors in search of a bargain, as the more the stock falls, the more discount value investors get on AGN stock.As Allergan launches new products this year, it will offset the negative impact of generic drug competition for Botox, making it an undervalued stock to watch. Innoviva (INVA)Innoviva (NASDAQ:INVA) is another stock in the drug space whose large drop starting in late January appears greatly overdone. The market all but erased the powerful uptrend in the stock that began after INVA sold off in November 2018 and bottomed at $14.The FDA approved Mylan's (NASDAQ:MYL) generic version of Advair, which GlaxoSmithKline (NYSE:GSK) produces. This forced investors to worry about Innoviva's prospects because the company is paid royalties from Glaxo. In the third quarter, Innova received $65.1 million in royalty revenues from Glaxo; $51.7 million came from global net sales of Revar/Breo Ellipta.On Feb. 6, Innoviva reported revenue of $79.86 million, up 14.9% from last year. With the stock trading at a forward price-to-earnings ratio of 7.7, the price-earnings-to-growth ratio is 0.39. As such, this general pessimism has created an appealing entry point to INVA stock. * 7 Winning High-Yield Dividend Stocks With Payouts Over 5% Investors appear to be overreacting to the generic competition. If demand for Innoviva's formulation does not drop and prices hold, royalty revenues should not fall as much as markets think, which makes INVA an ideal undervalued stock to invest in now. Vodafone (VOD)Telecom stocks are out of favor. For example, just look at AT&T (NYSE:T), which is down over 20% from its 52-week high. But Vodafone (NASDAQ: VOD) is down the most among the major names in the sector, falling over 40% from its 52-week high.Third-quarter results for VOD, which ended on Dec. 31, missed analysts' consensus sales forecasts. Vodafone continued to under-perform in Europe, due to rising competition. Although the company highlighted improving customer trends in Italy, Germany, and reduced churn in Spain, this was not enough to prevent revenue falling 5.6% in Europe and 6.8% overall.With all that bad news, it is little wonder why the stock has been marching lower. But VOD still has ways to mend the wound. The company could trim the dividend and re-allocate its resources toward advertising and capital expenditures. That would put it in a better position to compete with its European counterparts. And the stock would respond if those efforts lead to better revenue numbers.Vodafone shares pay a dividend yield in excess of 6%. If Vodafone grows its U.K. business as it signs on users to its 5G services and cuts costs as it signs on more customers, VOD stock will finally move higher.As of this writing, Chris Lau owned shares of Innoviva. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 15 Stocks Sitting on Huge Piles of Cash * The 10 Best Stocks to Buy for the Bull Market's Anniversary * 7 Dividend Stocks With Big Yields Compare Brokers The post 5 Undervalued Stocks to Invest In appeared first on InvestorPlace.

  • Insys Plunges on Auditor's Concern About Insufficient Funds
    Zackslast month

    Insys Plunges on Auditor's Concern About Insufficient Funds

    Insys Therapeutics' (INSY) shares plunge after its auditor raises concerns related to insufficiency of funds to continue operations.

  • The Wall Street Journallast month

    SEC Closes Probe Into Mylan's Real-Estate Dealings with Former Director

    NV said the Securities and Exchange Commission closed a three-year-old investigation into real-estate dealings with a former director, without taking any enforcement action. The SEC had been looking into whether Mylan failed to properly disclose real-estate deals involving the company and its then-lead outside director, who has since left the board. The SEC issued a subpoena in the matter in September 2015.

  • Reuterslast month

    FDA approves generic valsartan amid drug shortage

    The U.S. Food and Drug Administration on Tuesday approved a new generic of heart medicine valsartan and said it prioritized the drug's review to help relieve recent shortage as manufacturers around the ...